Inclusion Criteria:  Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study. Male or female, aged 18-85 Diagnosed with q-PCR confirmed infection with SARS-Cov-2 virus and admitted to the hospital. Receiving non-invasive respiratory support through a nasal cannula or a face mask. Ability to take oral medication and be willing to adhere to the tazemetostat regimen.  Exclusion Criteria:  Unable to take PO medication. Need for intubation or ECMO. Pregnancy or lactation Known allergic reactions to tazemetostat. Active malignancy (not in remission). Treatment with another investigational drug.